SequelSEC

Mereo BioPharma Group plc MREO

Pharmaceutical Preparations · CIK 0001719714 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$500.00K
Fiscal year ended 2025-12-31
Operating income
-$40.11M
Fiscal year ended 2025-12-31
Free cash flow
-$30.99M
Fiscal year ended 2025-12-31

Mereo BioPharma Group plc (MREO) reported revenue of $500.00K and net income of -$41.88M for the fiscal year ended 2025-12-31. This page shows 4 annual periods of income statement, balance sheet and cash flow figures normalized from Mereo BioPharma Group plc’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Mereo BioPharma Group plc income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-31
Revenue$500.00K$0$10.00M$0
Cost of revenueUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailable
Operating income-$40.11M-$47.36M-$28.42M-$54.43M
Net income-$41.88M-$43.25M-$29.47M-$42.22M
Research & development$17.77M$20.93M$17.42M$29.46M
Weighted-average diluted sharesshares 797.12Mshares 739.62Mshares 659.45Mshares 603.20M
Pretax income-$41.88M-$43.25M-$30.00M-$42.94M
Income tax expense$0$0-$532.00K-$718.00K
Diluted EPS$-0.05$-0.06$-0.04$-0.07
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailable
General & administrative$23.01M$26.43M$18.42M$26.11M
Selling & marketingUnavailableUnavailableUnavailableUnavailable

Balance

Mereo BioPharma Group plc balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-31
Cash & equivalents$40.99M$69.80M$57.42M$68.18M
Total assets$45.92M$76.39M$66.50M$77.41M
Current assets$45.02M$74.76M$63.76M$75.20M
Total liabilities$5.00M$15.42M$15.96M$26.01M
Current liabilities$4.30M$13.85M$9.49M$24.38M
Total equity incl. NCI$40.92M$60.97M$50.54M$51.40M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailable
Accounts payable$1.33M$2.44M$2.35M$3.49M

Cash flow

Mereo BioPharma Group plc cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-31
Operating cash flow-$30.97M-$32.83M-$21.13M-$48.82M
Capital expenditures$20.00K$0$0$13.00K
Investing cash flow-$20.00K-$699.00K-$419.00K$1.99M
Financing cash flow$327.00K$46.15M$7.97M$200.00K
Net change in cashUnavailable$12.38M-$10.76MUnavailable
Stock-based compensation$7.60M$7.39M$4.92M$4.77M
Common dividends paidUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailable

Derived

Mereo BioPharma Group plc derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-31
Free cash flow-$30.99M-$32.83MUnavailable-$48.83M
Gross marginUnavailableUnavailableUnavailableUnavailable
Operating margin-8021.4%Unavailable-284.2%Unavailable
FCF margin-6198.2%UnavailableUnavailableUnavailable
SBC / revenue1519.6%Unavailable49.2%Unavailable
Current ratio10.46x5.40x6.72x3.09x
Revenue YoY growthUnavailable-100.0%UnavailableUnavailable
Net margin-8375.6%Unavailable-294.7%Unavailable
R&D / revenue3553.2%Unavailable174.2%Unavailable
CapEx / revenue4.0%UnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open MREO in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-11View SEC filing
10-Q · Filed 2026-05-12View SEC filing
10-K · Filed 2026-03-19View SEC filing
10-Q · Filed 2025-11-10View SEC filing
10-Q · Filed 2025-08-12View SEC filing
10-Q · Filed 2025-05-13View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.